Artivion, Inc. (NYSE:AORT – Get Free Report) SVP Andrew Green sold 6,510 shares of Artivion stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $27.27, for a total value of $177,527.70. Following the completion of the sale, the senior vice president directly owned 53,133 shares in the company, valued at $1,448,936.91. This represents a 10.91% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Artivion Stock Performance
Shares of AORT stock opened at $25.59 on Monday. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -365.52 and a beta of 1.25. The stock has a 50 day simple moving average of $26.09 and a 200-day simple moving average of $29.16. Artivion, Inc. has a 12-month low of $19.16 and a 12-month high of $48.25. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82.
Artivion (NYSE:AORT – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.The firm had revenue of $125.76 million for the quarter, compared to the consensus estimate of $119.99 million. On average, equities analysts forecast that Artivion, Inc. will post 0.45 EPS for the current year.
Institutional Investors Weigh In On Artivion
Analyst Ratings Changes
AORT has been the topic of a number of recent analyst reports. Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Weiss Ratings cut shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen lowered shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Canaccord Genuity Group increased their target price on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Finally, Stifel Nicolaus set a $45.00 price target on shares of Artivion in a research report on Monday, June 1st. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $44.83.
Get Our Latest Research Report on AORT
Artivion Company Profile
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Read More
- Five stocks we like better than Artivion
- AI Token Costs Are Changing the Hardware vs. Software Debate
- 3 ETFs That Could Move as Rate Expectations Shift
- 3 Stocks With September Catalysts Investors Shouldn’t Ignore
- Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
